ScholarWorks@Dongguk University: Han, Hyo kyung

Detailed Information

Han, Hyo kyung (한효경)

College of Pharmacy (Department of Pharmacy)

Research Area

Tel 031-961-5217
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Aminoclay:11||aminoclay:7||dissolution:7||solid dispersion:4||Bioavailability:4||bioavailability:4||Dissolution:4||Nanocarrier:3||Liposome:3||Nanocomposite:3||Solid dispersion:3||Oral delivery system:3||solubilization:2||Sorafenib:2||Insulin:2||Protein drug:2||topotecan:2||BCRP inhibitor:2||poloxamer 407:2||Asthma:2||LW6:2||Inflammation:2||Machine learning:2||Epithelialmesenchymal transition:2||3Aminopropyl functionalized magnesium phyllosilicate:2||Pharmacokinetics:2||Cytotoxicity:2||formulation:2||Infliximab:2||XGBoost:2||Drug delivery:2||solubility:2||Chemotaxis:1||Chemotherapeutics:1||Chitosan:1||Chrysin:1||Coenzyme Q10:1||Colon targeting:1||Colontargeted:1||Colonic absorption:1||Colonic delivery:1||Content uniformity:1||Continuous manufacturing:1||Coumarin6:1||Curcumin:1||DK1108:1||Delivery:1||Diabetes:1||Distribution imaging:1||Dosage forms:1||Drug carrier:1||Drug development:1||Drug resistance:1||E. coli:1||ELISA:1||EMP2:1||Ethacrynic acid:1||Eudragit (R) RL PO:1||Eudragit (R) RS PO:1||Eudragit (R) RSPO:1||Eudragit S100:1||Factors:1||Fenofibrate:1||Folate receptor:1||Formulation:1||FoxO1:1||GLP1 agonist:1||Gene delivery:1||Glycol chitosan:1||Guidelines:1||H2O2:1||HCV replication inhibitors:1||HIF1α inhibition:1||HepG2 cells:1||Hepatitis C virus:1||Hotmelt extrusion:1||Hyaluronic acid:1||Hydrophobic fractions:1||IC50:1||ICAM1:1||IL1 beta:1||Indole derivatives:1||Inflammatory airway disease:1||Inflammatory bowel disease:1||Inflammatory disease:1||Inhibitor:1||Insoluble polymer:1||Key Words:1||LCMS:1||LCMS/MS:1||Lactate dehydrogenase leakage assay:1||Leukotriene B4 (LTB4):1||Leukotriene B4 receptor 2 (BLT2):1||Lignans:1||Lipid nanoparticle (LNP):1||Liposomes:1||Liraglutide:1||Low dose drugs:1||Lun cancer:1||M cell targeting:1||MAPK:1||MAPK pathway:1||MRP2:1||MS:1||MT102:1||Melanogenesis:1||Melanosome transfer:1||Menadione:1||Messenger RNA:1||Microfluidic device:1||Microneedles:1||Microprecipitated bulk powder:1||Multidrug resistance:1||Nanobiohybrid:1||Nanocomposite carrier:1||Nanocomposites:1||Nanomedicine:1||Nanomedicines:1||Nanotechnology:1||Natureinspired chiralfree benzofuran:1||Noninvasive:1||Nonparenteral:1||OATP1B1:1||OATP1B3:1||Obesity:1||Omega3 phospholipids:1||Oral bioavailability:1||Oral delivery:1||Oral exposure:1||Organophyllosilicates:1||Pglycoprotein:1||Pgp:1||PRR16:1||Paclitaxel:1||Patientderived cancer organoid:1||Pelubiprofen:1||Personalized medicine:1||Pharmaceutical application:1||Pharmacoprinting:1||Physical stability:1||Piperine:1||Plasma:1||Polypill:1||Prolonged circulation:1||Protein:1||Protein adsorption:1||Protein drugs:1||Proteins:1||RNAbinding protein:1||Rat:1||Reactive oxygen species:1||S. mutans:1||SIRT1:1||SPG membrane:1||STAT3:1||Saquinavir:1||Schisandra chinensis:1||Selectivity:1||Selfvalidated ensemble model:1||Silver nanoparticles:1||Skin permeation:1||Solubility:1||Solubilization:1||Sparassis latifolia:1||Stabilization:1||Structureactivity relationship (SAR) study:1||Support vector machines:1||Sustained release:1||TNFα:1||TPGS:1||TRP1:1||TRP2:1||TYR:1||Telmisartan:1||Th2 cytokines:1||Thermosensitive polymers:1||Tranilast:1||Transformation:1||Tumor targeting:1||Vaccine manufacturing:1||Vitamin Ks:1||acid instability:1||active coating:1||adenovirus:1||adipogenesis:1||alphaaminoepsiloncarprolactam:1||aminopropyl functionalized magnesium phyllosilicate:1||anticancer:1||antisolvent precipitation:1||autophagy:1||autotransplantation:1||betanin:1||bladder cancer:1||calciumsensing receptor:1||cancer:1||cell penetrating peptides:1||cell senescence:1||cell surface receptors:1||cellular uptake:1||chiral recognition:1||chiral stationary phase:1||chitosan:1||chromatographic separation:1||coating uniformity:1||colon:1||colonic delivery:1||colonic delivery system:1||colorectal cancer:1||combination:1||conformationally rigid:1||cryoprotectant:1||curcumin:1||cytochrome P450 enzymes:1||cytotoxicity:1||dendritic cells:1||diabetes:1||drug delivery system:1||drug interaction1:1||drug metabolizing enzymes:1||drug release:1||drugdiet interaction:1||enantiomer separation:1||fenofibrate:1||fibroblast:1||film coating:1||fluorescencebased assay:1||freezedrying:1||gemfibrozil:1||gene therapy:1||glibenclamide:1||gold nanoparticle:1||gut microbiota:1||herb–drug interactions:1||hnRNPA2B1:1||hydrophilic polymer:1||hypercalciuria:1||hypocalcemia:1||hypoparathyroidism:1||indirubin:1||inflammation:1||inflammatory bowel diseases:1||intravenous IgG (IVIG):1||krill oil:1||lipidbased formulation:1||lipopolysaccharide (LPS):1||liposome:1||liraglutide:1||luminescencebased assay:1||lyophilization:1||lyoprotectant:1||membrane emulsification:1||methotrexate:1||miR1299:1||microbead:1||modeling:1||mucoadhesiveness:1||multilayered tablet:1||nanocomposite:1||noninvasive drug delivery:1||obesity:1||omega3 phospholipids:1||oral absorption:1||oral bioavailability:1||oral efficacy:1||oral formulation:1||organic clay:1||pH modifier:1||pHdependent:1||parathyroidectomy:1||pharmacokinetics:1||polymeric micelle:1||poorly watersoluble drugs:1||povidone K30:1||probiotic:1||protein:1||protein aggregation:1||protein assays:1||protein drugs:1||protein stability:1||quantitation:1||reconstitution:1||saikosaponin:1||selfmicroemulsifying drug delivery system:1||selfnanoemulsifying drug delivery system:1||semaglutide:1||solvate:1||stability:1||surface coating:1||sustainedrelease:1||tablet:1||tamoxifen resistant breast cancer:1||target selectivity:1||therapeutic adjuvant:1||tight junction opening:1||transduction:1||transporters:1||trehalose:1||tvalsartan:1||type 2 diabetes:1||3,5dinitrobenzoyl leucine:1||βglucan:1||3D printing:1||ABI2:1||ABL1 kinase:1||AC1497:1||AMP clay:1||AMPK pathway:1||ARG2:1||ARL1:1||ATPbinding cassette (ABC):1||Absorption:1||Adenovirus:1||Antioxidation:1||Antibody:1||Anticancer activity:1||Antisolvent:1||Artificial intelligence:1||Artificialneuralnetwork designofexperiment:1||B7H4:1||BCRP:1||BLT2 antagonist:1||Bacteria:1||Basroparib, tankyrase inhibitor:1||Bayesian optimization:1||Beta vulgarisL:1||Biflorin:1||Biomedicine:1||Breast cancer:1||Cancer:1||Cationic:1||Cefdinir:1||Chemical stability:1||

RSS_1.0 RSS_2.0 ATOM_1.0

30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE